{"filing":{"accession_number":"0001628280-26-063316","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"vtgn-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/vtgn-20260924.htm"},"events":[{"id":34723,"run_id":31968,"accession_number":"0001628280-26-063316","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vistagen disclosed positive exploratory efficacy data for fasedienol nasal spray presented at Psych Congress 2026, showing statistically significant improvements in anxiety symptoms in subpopulation analyses of participants with very severe social anxiety disorder. This represents a material clinical development milestone for the Company's Phase 3 product candidate, affecting investor assessment of pipeline progress and regulatory prospects, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other named event types. The disclosure is operational/strategic in nature—a clinical trial result announcement—and material to a biopharmaceutical company's valuation and development trajectory.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38544,"accession_number":"0001628280-26-063316","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen disclosed positive exploratory efficacy data for fasedienol nasal spray presented at Psych Congress 2026, showing statistically significant improvements in anxiety symptoms in subpopulation analyses of participants with very severe social anxiety disorder. This represents a material clinical development milestone for the Company's Phase 3 product candidate, affecting investor assessment of pipeline progress and regulatory prospects, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other named event types. The disclosure is operational/strategic in nature—a clinical trial result announcement—and material to a biopharmaceutical company's valuation and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:17:59.440927+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38544,"accession_number":"0001628280-26-063316","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen disclosed positive exploratory efficacy data for fasedienol nasal spray presented at Psych Congress 2026, showing statistically significant improvements in anxiety symptoms in subpopulation analyses of participants with very severe social anxiety disorder. This represents a material clinical development milestone for the Company's Phase 3 product candidate, affecting investor assessment of pipeline progress and regulatory prospects, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other named event types. The disclosure is operational/strategic in nature—a clinical trial result announcement—and material to a biopharmaceutical company's valuation and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:17:59.440927+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-09-24"}]}